We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Targeting the Interleukin 6 Receptor to Treat Neuromyelitis Optica

Sarosh R. Irani, MD, DPhil1; Angela Vincent, FRCPath1
[+] Author Affiliations
1Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, England
JAMA Neurol. 2015;72(7):747-748. doi:10.1001/jamaneurol.2015.0579.
Text Size: A A A
Published online


The number of different antibody-associated disorders of the central nervous system and the clinical phenotypes encountered are increasing steadily. Because these patients have potentially reversible diseases, it is incumbent on the neurologist to treat them promptly and effectively. However, although some diseases respond fairly well and quickly to conventional immunotherapies, some can be very challenging.

Neuromyelitis optica (NMO) is a severe and disabling condition caused by antibodies to the water channel aquaporin 4 (AQP4), which is expressed on the astrocyte end feet abutting the pia and vascular endothelium. Antibodies to AQP4 lead to complement-dependent inflammation and antigen internalization, and treatment aims to reduce antibody levels. However, as AQP4 antibodies seldom disappear, the patient remains susceptible to further inflammatory lesions of the optic nerve or spinal cord, with each relapse resulting in increased disability and a risk of permanent blindness or paralysis. Thus, relapse prevention must be a major goal of therapy. In addition, neuropathic pain, mostly related to spinal cord involvement, is a prominent and often treatment-resistant feature in NMO1 that has now become well recognized.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

1 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections